Name
Proteins
Accession Number
DBCAT000020
Description

Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.

Drugs
DrugDrug Description
LepirudinA protein-based direct thrombin inhibitor used to reverse and prevent thrombus formation in heparin-induced thrombocytopenia.
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
Dornase alfaA synthetic form of human deoxyribonuclease I used to break down extracellular DNA in the lungs, a major source of mucous viscosity in cystic fibrosis.
Denileukin diftitoxA recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor.
EtanerceptA protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
BivalirudinA direct thrombin inhibitor used to treat heparin-induced thrombocytopenia and to prevent thrombosis during percutaneous coronary intervention.
LeuprolideA peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty.
Peginterferon alfa-2aA modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
SermorelinFor the treatment of dwarfism, prevention of HIV-induced weight loss
Interferon alfa-n1A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
Darbepoetin alfaA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
GoserelinA synthetic analog of luteinizing hormone-releasing hormone used to treat breast cancer and prostate cancer by reducing secretion of gonadotropins from the pituitary.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
ErythropoietinA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
Salmon calcitoninA synthetic peptide form of calcitonin used to inhibit bone resorption in the treatment of hypercalcemia, osteoporosis, and Paget's disease.
Interferon alfa-n3A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
PegfilgrastimA recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
SargramostimA modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant.
Peginterferon alfa-2bA purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers.
Antihemophilic factor, human recombinantA form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.
Gramicidin DA bactericidal antibiotic used in the treatment of dermatological and ophthalmic infections.
Human immunoglobulin GA purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
Interferon gamma-1bA form of recombinant human interferon used to treat infections associated with chronic granulomatous disease and to slow the progression of severe malignant osteopetrosis.
DesmopressinA synthetic analog of vasopressin used to reduce renal excretion of water in central diabetes insipidus and nocturia.
Coagulation factor VIIa Recombinant HumanA form of recombinant human coagulation Factor VII used to treat hemophilia A and B.
OprelvekinA form of recombinant interleukin-11 used to stimulate production of megakaryocytes and platelets in patients with or at risk of thrombocytopenia after chemotherapy.
PaliferminA form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy.
GlucagonA form of recombinant glucagon used to treat hypoglycemia in diabetes mellitus and as a part of gastrointestinal imaging procedures.
AldesleukinA recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
Botulinum Toxin Type BA purified form of botulinum toxin type B used to block acetylcholine release in the treatment of cervical dystonia and sialorrhea.
OmalizumabA monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
CetrorelixA synthetic peptide antagonist of gonadotropin releasing hormone used to prevent luteinizing hormone surges in women undergoing assisted reproduction therapy.
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
Indium In-111 satumomab pendetideFor diagnosis of extrahepatic malignant cancers
Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
Interferon beta-1aA form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis.
Albumin humanA purified form of human serum albumin used to replace lost albumin in patients with hypoalbuminemia, to treat hypovolemia and ascites, and as a part of some diagnostic imaging kits.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
FollitropinA form of recombinant human follicle stimulating hormone used to stimulate follicle development in women with primary ovarian hypogonadism and in men with hypogonadotropic hypogonadism.
VasopressinA peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy.
Interferon beta-1bA form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.
Interferon alfacon-1A recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections.
Insulin porkA purified form of porcine insulin used to control hyperglycemia in diabetes mellitus.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
MuromonabA monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Ibritumomab tiuxetanA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
TositumomabA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Botulinum toxin type AA purified form of botulinum toxin type A used to block acetylcholine release in the treatment of chronic sialorrhea, muscle spasticity, and dystonia, as well as in cosmetic applications.
StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Capromab pendetideA monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
FelypressinFor use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.
EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Antithymocyte immunoglobulin (rabbit)A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
FilgrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
BecaplerminA recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
Agalsidase betaA form of recombinant human alpha-galactosidase A enzyme used to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide.
NatalizumabA monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
EnfuvirtideAn HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals.
PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
Technetium Tc-99m arcitumomabFor imaging colorectal tumors
CitrullineUsed for nutritional supplementation, also for treating dietary shortage or imbalance.
PentagastrinA gastrin-like molecule used as a diagnostic aid for the evaluation of gastric acid secretory function, gastric hypersecretion, and Zollinger-Ellison tumors.
PerflutrenA diagnostic medication to improve contrast during echocardiograms.
GonadorelinA synthetic GnRH used to test the function of gonadotropes and the pituitary.
NafarelinA gonadotropin releasing hormone agonist used to treat central precocious puberty.
ColistinA polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria.
Aminolevulinic acidA porphyrin precursor used to treat actinic keratosis of the face, scalp, and upper extremities, as well as to visualize a glioma.
ColistimethateAn antibiotic indicated for treatment of infections caused by susceptible strains of certain gram-negative bacilli. It is particularly useful for targeting sensitive strains of Pseudomonas aeruginosa.
EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
MecaserminA recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH.
PramlintideAn amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
GalsulfaseA recombinant human enzyme used as replacement enzyme therapy for the treatment of of adults and children with Mucopolysaccharidosis VI, a rare genetic disorder caused by a deficiency of a lysosomal enzyme.
AbataceptA disease-modifying antirheumatic drug (DMARD) used for the management of moderate-to-severe active rheumatoid arthritis and active polyarticular juvenile idiopathic arthritis as monotherapy or in combination with other DMARDs.
TetracosactideA diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency.
CorticotropinA diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency.
Insulin glulisineA short-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus.
CalciumA mineral found in over-the-counter supplements or prescription formulations used for the treatment of specific medical conditions related to calcium deficiency.
ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
Bacteriochlorophyll AA specific bacteriochlorophyll that is similar in structure to CHLOROPHYLL A.
Molybdenum cofactorAbsence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite...
Platelet Activating FactorNot Available
TerlipressinCommonly used to stop bleeding of varices in the food pipe (oesophagus).
VapreotideFor the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
NesiritideA recombinant natriuretic peptide used for the treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
ThymalfasinIndicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate...
GaliximabInvestigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
G17DTIntended for the treatment of various forms of cancer.
DirucotideFor the treatment of multiple sclerosis (MS).
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
AfamelanotideAn injectable subcutaneous implant used to mitigate phototoxicity secondary to erythropoietic protoporphyria (EPP).
HemoglobinAn iron-containing protein found in all red blood cells (RBCs) for proper binding of oxygen and transport throughout the body, included in blood transfusions in severe hemorrhage.
PexelizumabFor the treatment of inflammation during cardiac surgery.
AfelimomabInvestigated for use/treatment in sepsis and septicemia.
EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
BectumomabInvestigated for use/treatment in lymphoma (non-hodgkin's).
OregovomabInvestigated for use/treatment in ovarian cancer.
TigapotideFor the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.
IGN311Intended for the treatment of various forms of cancer.
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
LancovutideInvestigated for use/treatment in cystic fibrosis and eye disorders/infections.
REV131Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts.
AbaloparatideA parathyroid hormone-related protein (PTHrP) analog used for the treatment of osteoporosis in postmenopausal women with a high risk of fracture.
LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
LeptinInvestigated for use/treatment in lipodystrophy and obesity.
MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
NN344Investigated for use/treatment in diabetes mellitus type 1 and 2.
BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
CR002Investigated for use/treatment in nephropathy.
CR665Investigated for use/treatment in pain (acute or chronic).
TopsalysinInvestigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
ElafinInvestigated for use/treatment in inflammatory disorders (unspecified).
RozrolimupabInvestigated for use/treatment in thrombocytopenia.
Interferon alfaInvestigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
GlatiramerAn immunomodulator used to reduce the frequency of relapses in Multiple Sclerosis (MS).
Hepatitis B Immune GlobulinAn injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection.
keyhole limpet hemocyaninInvestigated for use/treatment in bladder cancer and solid tumors.
Cintredekin BesudotoxInvestigated for use/treatment in brain cancer.
Oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
ObiltoxaximabA monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
Ciliary neurotrophic factorInvestigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
CorticorelinInvestigated for use/treatment in brain cancer and neurologic disorders.
Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
XTL-001Investigated for use/treatment in hepatitis (viral, B).
TifuvirtideInvestigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
NAV 1800Investigated for use/treatment in colorectal cancer and solid tumors.
LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
AMG 108Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
IratumumabInvestigated for use/treatment in lymphoma (unspecified).
EnokizumabInvestigated for use/treatment in asthma.
RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
PraconaseInvestigated for use/treatment in spinal cord injuries.
FarletuzumabInvestigated for use/treatment in ovarian cancer.
Fibroblast growth factor-1Investigated for use/treatment in coronary artery disease and peripheral vascular disease.
IRX-2Investigated for use/treatment in cancer/tumors (unspecified), head and neck cancer, and solid tumors.
VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
TNX-901Investigated for use/treatment in allergic reaction.
NBI-6024Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications.
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
RI 624Investigated for use/treatment in pain (acute or chronic).
MYO-029Investigated for use/treatment in muscular dystrophy.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
CTCE-0214Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.
LeronlimabA humanized monoclonal antibody being investigated
GI-5005Investigated for use/treatment in hepatitis (viral, C).
Glembatumumab vedotinInvestigated for use/treatment in melanoma.
OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
IPH 2101Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
TB-402Investigated for use/treatment in atrial fibrillation and thrombosis.
CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
IMC-1C11Investigated for use/treatment in cancer/tumors (unspecified).
EldelumabInvestigated for use/treatment in ulcerative colitis.
IRL-1620Investigated for use/treatment in cancer/tumors (unspecified).
LumiliximabInvestigated for use/treatment in asthma and leukemia (lymphoid).
CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
NimotuzumabInvestigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
IcatibantA bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).
ClenoliximabInvestigated for use/treatment in rheumatoid arthritis.
TraferminInvestigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
LanoteplaseInvestigated for use/treatment in myocardial infarction.
AviptadilNot Annotated
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
BIIB015Investigated for use/treatment in solid tumors.
MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
AVE9633Investigated for use/treatment in leukemia (myeloid).
CarotuximabInvestigated for use/treatment in solid tumors.
AZX-100Investigated for use/treatment in scar tissue.
XmAb 2513Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
Coltuximab ravtansineInvestigated for use/treatment in lymphoma (non-hodgkin's).
TeprotumumabA fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease.
LucatumumabInvestigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
RilonaceptAn IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
Calcitonin gene-related peptideInvestigated for use/treatment in myocardial infarction, heart disease, and asthma.
AtaciceptInvestigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
EndostatinInvestigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
RepiferminInvestigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease.
ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
SibrotuzumabInvestigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
VelaferminInvestigated for use/treatment in adverse effects (chemotherapy).
OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
AMGN-0007Investigated for use/treatment in osteoporosis and bone metastases.
ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
LabradimilInvestigated for use/treatment in brain cancer and pediatric indications.
BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
LerdelimumabInvestigated for use/treatment in glaucoma and cataracts.
EmfilerminInvestigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.
BaminerceptInvestigated for use/treatment in rheumatoid arthritis.
TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
LexatumumabInvestigated for use/treatment in cancer/tumors (unspecified).
ReslizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
TeplizumabInvestigated for use/treatment in diabetes mellitus type 1.
CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
MepolizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
LiraglutideA GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes.
PasireotideA somatostatin analog used in the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery is not appropriate.
GolimumabA TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
BelataceptA selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
AprotininA serine protease inhibitor used to reduce the risk for perioperative blood loss and the need for blood transfusion in high-risk patients during cardiopulmonary bypass for coronary artery bypass graft surgery.
BuserelinA LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females.
SaralasinNot Annotated
GanirelixA GnRH antagonist used in assisted reproduction in women undergoing controlled ovarian hyperstimulation to control ovulation by inhibiting the premature LH surges.
HistrelinA GnRH agonist found in subcutaneous implants used for the treatment of pediatric patients with central precocious puberty and the palliative treatment of advanced prostate cancer.
LanreotideA somatostatin analog used for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly.
TriptorelinA GnRH agonist indicated for the palliative treatment of advanced prostate cancer.
DADLEA delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.
DPDPEA heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
TesamorelinA growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
BelimumabA B-lymphocyte stimulator (BLyS)-specific inhibitor that indirectly inhibits B cell survival, and is used to treat patients with autoantibody positive, active systemic lupus erythematosus.
AfliberceptA vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
TeduglutideA glucagon-like peptide-2 (GLP-2) analog used to treat patients with Short Bowel Syndrome (SBS) who require parenteral nutritional support.
RaxibacumabA monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
SecukinumabAn immunomodulating agent and interleukin antagonist used to manage moderate to severe plaque psoriasis and active psoriatic arthritis or ankylosing spondylitis.
VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
AlbiglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
MetreleptinA leptin analogue used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
BlinatumomabAn antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Corticorelin ovine triflutateA synthetic corticotropin-releasing hormone used for diagnostic purposes in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
SomatostatinA naturally-occurring peptide hormone used for the symptomatic treatment of acute bleeding from esophageal varices.
AncestimA human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection.
Asfotase alfaAn enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
Methoxy polyethylene glycol-epoetin betaA synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease.
Turoctocog alfaAn antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).
Peginterferon beta-1aAn interferon beta used to treat relapsing forms of multiple sclerosis.
Chorionic Gonadotropin (Human)A naturally-occurring hormone produced during human placenta used for the treatment of prepubertal cryptorchidism and hypogonadotropic hypogonadism in selected males, and induction of pregnancy in selected infertile women.
Protamine sulfateA blood factor used when the reversal of the anticoagulant effect of heparin is necessary and for the treatment of heparin overdose.
PolaprezincPeptic ulcer disease, dyspepsia .
Fibrinogen humanA hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
AlirocumabA PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
EvolocumabA PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma.
Gastric intrinsic factorIntrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic...
ProtirelinA synthetic analogue of thyrotropin-releasing hormone that has been used during diagnostic tests to evaluate function of the thyroid gland.
Secretin porcineA secretin hormone used to stimulate pancreatic or gastric secretions to diagnose exocrine pancreas dysfunction, gastrinoma, and abnormalities in the bile and pancreatic ducts.
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
CaseinAn extract from Casein used in allergy testing.
Bordetella pertussis pertactin antigenBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis .
DesirudinIndicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Iron protein succinylateNot Annotated
GelatinGelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also...
ThioredoxinThioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. It is a 12-kD oxidoreductase enzyme encoded by TXN...
ThrombinA coagulation factor used to stop bleeding during surgery.
ProthrombinA coagulation factor used for emergency reversal of vitamin K antagonist therapy.
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
Factor IX Complex (Human)A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy.
DeslorelinDeslorelin acetate is an injectable gonadotropin releasing hormone super-agonist also known as an LHRH agonist. It stops the production of sex hormones.
IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
Antithrombin III humanAn alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
Human Varicella-Zoster Immune GlobulinA solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
Epoetin deltaEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Eptotermin AlfaA bone morphogenetic protein that is widely expressed during EMBRYONIC DEVELOPMENT. It is both a potent osteogenic factor and a specific regulator of nephrogenesis. Eptotermin Alfa is an ingredient in...
Dibotermin alfaindicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. indicated for single-level...
ConatumumabConatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
BremelanotideBremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition, problems with the relationship, or the effects of...
TabalumabTabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
Rusalatide acetateChrysalin has been used in trials studying the treatment of Radius Fracture.
FiclatuzumabFiclatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
FigitumumabFigitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
VonapanitaseVonapanitase is under investigation for the treatment of Chronic Kidney Disease.
CarnosineCarnosine has been investigated for the treatment of Gulf War Illness.
SetmelanotideSetmelanotide has been investigated for the treatment of obesity.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
BapineuzumabBapineuzumab has been investigated for the treatment of Alzheimer's Disease.
BombesinBombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and...
OnartuzumabOnartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
SolanezumabSolanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
TremelimumabTremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part...
BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
Neuropeptide YNeuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.
SirukumabSirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
GuselkumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DalotuzumabDalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Angiotensin IIA peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock.
EmibetuzumabEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
LigelizumabLigelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others.
SeribantumabSeribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
LandogrozumabLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
RomosozumabA monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
AvoterminJuvista has been investigated for the treatment, prevention, and basic science of Scars, Keloid, and Cicatrix.
CrenezumabCrenezumab has been used in trials studying the treatment of Alzheimer's Disease.
RilotumumabRilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
TAK-448TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
AnifrolumabAnifrolumab has been investigated for the treatment of Scleroderma.
OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
Interleukin-7Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Thymosin beta-4Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.
GantenerumabGantenerumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
UlinastatinUlinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
VisilizumabVisilizumab has been investigated for the treatment of Ulcerative Colitis.
TrebananibTrebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon...
NagrestipenNagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.
TT-232Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).
Lorvotuzumab mertansineLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
PatritumabPatritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
FulranumabFulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
TarextumabTarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
SotaterceptSotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.
GevokizumabGevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
BradykininBradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.
Vanutide cridificarVanutide cridificar has been investigated for the treatment of Alzheimer Disease.
DuligotuzumabDuligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
DupilumabA monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
TralokinumabTralokinumab is under investigation for the treatment of Alopecia Areata. Tralokinumab has been investigated for the treatment of Asthma.
BinetrakinBinetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
EtrolizumabEtrolizumab has been used in trials studying the treatment of Crohn Disease and Ulcerative Colitis.
GanitumabGanitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
EtaracizumabEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Polatuzumab vedotinThis medication is indicated to treat adults with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more...
InclacumabInclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
CixutumumabCixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant...
AscrinvacumabAscrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
AducanumabAducanumab has been used in trials studying the treatment of Alzheimer's Disease.
BlisibimodBlisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
TanezumabTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
DulanerminDulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.
DusigitumabDusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
FresolimumabFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
Vatreptacog alfaVatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
MuplestimMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in...
BococizumabBococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
ConberceptConbercept has been investigated for the basic science of Age-related Macular Degeneration.
Mirvetuximab SoravtansineMirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.
SelepressinSelepressin has been used in trials studying the treatment of Septic Shock.
MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
MolgramostimMolgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.
InebilizumabA humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD).
MavrilimumabMavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
BlosozumabBlosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
TecemotideTecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
BimagrumabBimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
PentetreotidePentetreotide has been used in trials studying the diagnostic of cushing syndrome.
TovetumabTovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
SpriferminSprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury of Knee.
Nerve Growth FactorNerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others.
Endothelin-1Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
AviscumineCy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
IbalizumabA CD4-specific antibody used to treat HIV infections.
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
IntetumumabIntetumumab has been used in trials studying the treatment of Melanoma.
CarlumabCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
FirategrastFirategrast has been used in trials studying the treatment of Multiple Sclerosis.
DemcizumabDemcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
TiplimotideTiplimotide has been used in trials studying the treatment of Multiple Sclerosis.
Zoptarelin doxorubicinZoptarelin doxorubicin has been used in trials studying the treatment of Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, and Urothelial Carcinoma, among others.
AbituzumabAbituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
SomatoprimSomatoprim is under investigation for the treatment of Acromegaly.
Naptumomab EstafenatoxNaptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
CrotedumabCrotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
ConcizumabConcizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
Pancreatic PolypeptidePancreatic Polypeptide has been investigated for the treatment of Diabetes Mellitus, Type 1.
DepatuxizumabDepatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
Olipudase alfaOlipudase alfa has been used in trials studying the treatment of Sphingomyelin Lipidosis and Human Acid Sphingomyelinase Deficiency.
RontalizumabRontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
AmatuximabAmatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
ClazakizumabClazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Interleukin-10Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others.
OzanezumabOzanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.[L13002]
Factor XIII (human)A purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency.
IsoxaflutoleBalance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
MilatuzumabMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
RobatumumabRobatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.
Urocortin-2Urocortin 2 has been investigated for the basic science of Heart Failure and Cardiovascular Disease.
RacotumomabRacotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
OlokizumabOlokizumab has been used in trials studying the treatment of Crohn's Disease.
Von Willebrand Factor HumanA complex of von Willebrand Factor and Factor VIII used to treat bleeding episodes in von Willebrand disease.
LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of...
Coagulation factor X humanA coagulation factor used to treat Factor X deficiency to control bleeding.
Protein S humanA medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
Coagulation factor VII humanA coagulation factor used to treat bleeding disorders such as hemophilia and Glanzmann's thrombasthenia.
Antihemophilic factor humanA Factor VIII replacement therapy used to treat hemophilia A.
KallidinogenaseNot Annotated
LipegfilgrastimA medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy.
Trenonacog alfaHuman coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells.
AlsactideNot Annotated
SulglicotideNot Annotated
EdrecolomabNot Annotated
OrnipressinNot Annotated
AngiotensinamideNot Annotated
NebacumabNot Annotated
SaruplaseNot Annotated
ElcatoninNot Annotated
Hemoglobin crosfumarilHemoglobin in which the alpha-subunit are cross-linked intramolecularly.
Human cytomegalovirus immune globulinA solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants.
EmicizumabAn antibody against Factor IXa and Factor X used to treat hemophilia A.
SemaglutideA glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus.
Nonacog beta pegolA recombinant coagulation Factor IX derivative used to treat hemophilia B.
Plasma protein fraction (human)A plasma protein solution used to treat coagulation factor deficiencies, reverse anticoagulant effects, and shock from a loss of plasma fluids, and is also used in plasma exchange procedures.
SulesomabMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
BesilesomabA monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
Moroctocog alfaA recombinant Factor VIII used to treat hemophilia A to control bleeding.
TildrakizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
TaspoglutideTaspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted...
ErenumabA calcitonin-gene related peptide antagonist used to prevent migraines.
FremanezumabA humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
Interleukin-1 alpha, human recombinantNot Annotated
Basic Fibroblast Growth FactorBasic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
NepiderminNot Annotated
FanolesomabAn anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
Insulin-like growth factor IIThe insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth...
Beroctocog alfaBeroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in...
Secretin humanA secretin hormone used to stimulate pancreatic or gastric secretions to diagnose exocrine pancreas dysfunction, gastrinoma, and abnormalities in the bile and pancreatic ducts.
Andexanet alfaA recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban.
LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
Antihemophilic Factor (Recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)...
LypressinNot Annotated
Moxetumomab PasudotoxA CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
ElapegademaseA recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency.
Indium In-111 pentetreotideIndium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
LebrikizumabLebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
BenralizumabA monoclonal antibody used to treat eosinophilic asthma.
ZalutumumabZalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
PlozalizumabPlozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
SifalimumabSifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,...
EmapalumabAn interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
DiaPep 277Investigated for use/treatment in diabetes mellitus type 1, autoimmune diseases, and diabetes mellitus type 2.
Turoctocog alfa pegolTuroctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of...
Polymyxin BA polymyxin antibiotic used to treat a wide variety of infections in the body.
VitespenInvestigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.
GirentuximabInvestigated for use/treatment in gall bladder cancer and renal cell carcinoma.
RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
Sar9, Met (O2)11-Substance PInvestigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection.
Peginterferon lambda-1aPeginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).
Anetumab ravtansineAnetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
IsatuximabA chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
ProcalcitoninProcalcitonin is under investigation in clinical trial NCT03440060 (Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD).
IcrucumabIcrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
PRM-151PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
Human interleukin-2Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
UteroglobinUteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).
VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
EmactuzumabEmactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
RefanezumabRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
PamrevlumabPamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
PateclizumabPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
Human interferon betaA polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
ApomabApomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
AbrilumabAbrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
AnfibatideAnfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).
LeridistimLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
TigatuzumabTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
UtomilumabUtomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
ZolbetuximabZolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).
Interferon alfa-2cInterferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
PonezumabPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AsunerceptAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
SuvratoxumabSuvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Gastric inhibitory polypeptideGastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
MitazalimabMitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).
AvidinAvidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
BleselumabBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant...
EdratideEdratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
BevifimodBevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).
DAS-181DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).
Valanafusp alfaValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
IstiratumabIstiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
PidilizumabPidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
ALT-801ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
GMA-161GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
Tucotuzumab celmoleukinTucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...
Ladiratuzumab vedotinLadiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
TomaralimabTomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
VesencumabVesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Pinatuzumab vedotinPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
Lulizumab pegolLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Lorukafusp alfaLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Naratuximab emtansineNaratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
rGLP-1Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2.
CT-011Investigated for use/treatment in cancer/tumors (unspecified).
Contulakin-GInvestigated for use/treatment in pain (acute or chronic).
SonepcizumabInvestigated for use/treatment in solid tumors.
OmigananInvestigated for use/treatment in bacterial infection and rosacea.
GlucarpidaseA carboxypeptidase enzyme used to treat toxic plasma methotrexate concentrations by providing an alternate elimination pathway for methotrexate in patients who have impaired renal function.
Thrombin alfaA platelet activating factor used to treat minor bleeding.
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria.
Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
Angiotensin 1-7TXA127 has been investigated for the treatment of Miscellaneous Peripheral Blood Cell Abnormalities.
EndostarEndostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
Depatuxizumab mafodotinNo approved indication.
UblituximabUblituximab has been used in trials studying the treatment of B-cell Lymphoma, Neuromyelitis Optica, Mantle Cell Lymphoma, Non-Hodgkins Lymphoma, and Marginal Zone Lymphoma, among others.
Vadastuximab TalirineVadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
VarlilumabVarlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
UrelumabUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody...
SimtuzumabSimtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
FasinumabFasinumab has been used in trials studying the basic science and treatment of Sciatica, Back Pain, Low Back Pain, Osteoarthritis, Hip, and Abdominal Pain Upper, among others.
Abicipar PegolAbicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration.
LuspaterceptAn erythroid maturation agent used to treat anemia secondary to beta thalassemia in patients requiring regular red blood cell transfusions.
GS-5745GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
VanucizumabVanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
Labetuzumab govitecanLabetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
EnsituximabEnsituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer.
FezakinumabFezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
Indusatumab vedotinIndusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
AclerastideAclerastide has been investigated for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic.
LumretuzumabLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
EcromeximabEcromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
PegvaliaseAn enzyme used to treat phenylketonuria in patients with phenylalanine levels that are too high on current treatment.
BimekizumabBimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis.
AlbusomatropinAlbusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency.
Rovalpituzumab TesirineRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
NamilumabNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
TregalizumabTregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
BezlotoxumabA monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
Anti-inhibitor coagulant complexA medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B.
Cerliponase alfaAn enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
TisagenlecleucelA CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.
Albutrepenonacog alfaA recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.
BurosumabA fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
EptinezumabA monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
LecanemabLecanemab is an experimental drug that is currently in clinical trials for the treament of Alzheimer's disease.
CemiplimabA programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
TagraxofuspA CD123-directed cytotoxin used to treat plasmacytoid dendritic cell neoplasm.
CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
SetrusumabSetrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
CodrituzumabCodrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
XentuzumabXentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
ParsatuzumabParsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
RozanolixizumabRozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
OpicinumabOpicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Trastuzumab deruxtecanAn antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
MargetuximabMargetuximab is under investigation in clinical trial NCT03133988 (Margetuximab Expanded Access Program).
GremubamabGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
TafasitamabTafasitamab is under investigation in clinical trial NCT02005289 (Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated...
FrovocimabFrovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
TezepelumabTezepelumab is under investigation in clinical trial NCT03406078 (Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma).
Telisotuzumab vedotinTelisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
RemtolumabRemtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).
BempegaldesleukinBempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib...
BPI-3016BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects).
PegilodecakinPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
TirzepatideTirzepatide is under investigation in clinical trial NCT03311724 (A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes).
NemolizumabNemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
GedivumabGedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
Vocimagene amiretrorepvecVocimagene amiretrorepvec is under investigation in clinical trial NCT02576665 (A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca...
Sofituzumab vedotinSofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
EvinacumabEvinacumab is under investigation in clinical trial NCT03146416 (Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers).
PegbelferminPegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
SOR-C13SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Silk sericinNot Annotated
ZenocutuzumabZenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
PadeliporfinNot Annotated
InolimomabInolimomab is under investigation in clinical trial NCT04289103 (Evaluation of Efficacy and Safety of Leukotac (Inolimomab) in Pediatric Patients With Sr-agvhd).
Edodekin alfaEdodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or...
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
Drugs & Drug Targets
DrugTargetType
LepirudinProthrombintarget
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
Dornase alfaDNAtarget
Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
Denileukin diftitoxCytokine receptor common subunit gammatarget
Denileukin diftitoxInterleukin-2 receptor subunit betatarget
EtanerceptTumor necrosis factortarget
EtanerceptLymphotoxin-alphatarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
EtanerceptComplement component 1q (C1q)target
BivalirudinProthrombintarget
BivalirudinMyeloperoxidaseenzyme
LeuprolideGonadotropin-releasing hormone receptortarget
Peginterferon alfa-2aInterferon alpha/beta receptor 2target
Peginterferon alfa-2aInterferon alpha/beta receptor 1target
Peginterferon alfa-2aCytochrome P450 1A2enzyme
AlteplaseUrokinase plasminogen activator surface receptortarget
AlteplaseFibrinogen alpha chaintarget
AlteplasePlasminogentarget
AlteplasePlasminogen activator inhibitor 1target
SermorelinGrowth hormone-releasing hormone receptortarget
Interferon alfa-n1Interferon alpha/beta receptor 2target
Interferon alfa-n1Interferon alpha/beta receptor 1target
Interferon alfa-n1Cytochrome P450 1A2enzyme
Darbepoetin alfaErythropoietin receptortarget
UrokinaseUrokinase plasminogen activator surface receptortarget
UrokinasePlasminogentarget
UrokinasePlasminogen activator inhibitor 2target
UrokinasePlasminogen activator inhibitor 1target
UrokinasePlasma serine protease inhibitortarget
UrokinaseNidogen-1target
UrokinaseLow-density lipoprotein receptor-related protein 2target
UrokinaseSuppressor of tumorigenicity 14 proteintarget
UrokinaseMacrophage metalloelastaseenzyme
GoserelinLutropin-choriogonadotropic hormone receptortarget
GoserelinGonadotropin-releasing hormone receptortarget
ReteplaseFibrinogen alpha chaintarget
ReteplasePlasminogentarget
ReteplasePlasminogen activator inhibitor 1target
ErythropoietinErythropoietin receptortarget
Salmon calcitoninCalcitonin receptortarget
Interferon alfa-n3Interferon alpha/beta receptor 1target
Interferon alfa-n3Interferon alpha/beta receptor 2target
Interferon alfa-n3Cytochrome P450 1A2enzyme
PegfilgrastimGranulocyte colony-stimulating factor receptortarget
PegfilgrastimNeutrophil elastaseenzyme
SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
SargramostimBone marrow proteoglycantarget
SargramostimInterleukin-3 receptor subunit alphatarget
SargramostimCytokine receptor common subunit betatarget
SargramostimSyndecan-2target
Peginterferon alfa-2bInterferon alpha/beta receptor 1target
Peginterferon alfa-2bInterferon alpha/beta receptor 2target
Peginterferon alfa-2bCytochrome P450 1A2enzyme
Peginterferon alfa-2bCytochrome P450 2D6enzyme
Peginterferon alfa-2bCytochrome P450 2C9enzyme
Antihemophilic factor, human recombinantCoagulation factor Xtarget
Antihemophilic factor, human recombinantPhytanoyl-CoA dioxygenase, peroxisomaltarget
Antihemophilic factor, human recombinantCoagulation factor IXtarget
Antihemophilic factor, human recombinantAsialoglycoprotein receptor 2target
Antihemophilic factor, human recombinant78 kDa glucose-regulated proteintarget
Antihemophilic factor, human recombinantCalreticulintarget
Antihemophilic factor, human recombinantCalnexintarget
Antihemophilic factor, human recombinantProtein ERGIC-53target
Antihemophilic factor, human recombinantProlow-density lipoprotein receptor-related protein 1target
Antihemophilic factor, human recombinantMultiple coagulation factor deficiency protein 2target
Antihemophilic factor, human recombinantvon Willebrand factortarget
Antihemophilic factor, human recombinantProthrombinenzyme
Antihemophilic factor, human recombinantVitamin K-dependent protein Cenzyme
AnakinraInterleukin-1 receptor type 1target
Gramicidin DP-glycoprotein 1transporter
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor Itarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-atarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor IBtarget
Human immunoglobulin GComplement C3target
Human immunoglobulin GComplement C4-Atarget
Human immunoglobulin GComplement C4-Btarget
Human immunoglobulin GComplement C5target
AnistreplaseFibrinogen alpha chaintarget
AnistreplasePlasminogentarget
AnistreplasePlasminogen activator inhibitor 1target
TenecteplaseUrokinase plasminogen activator surface receptortarget
TenecteplasePlasminogen activator inhibitor 1target
TenecteplaseFibrinogen alpha chaintarget
TenecteplasePlasminogen activator inhibitor 2target
TenecteplaseTetranectintarget
TenecteplaseKeratin, type II cytoskeletal 8target
TenecteplaseAnnexin A2target
TenecteplaseCalreticulintarget
TenecteplaseCalnexintarget
TenecteplaseProlow-density lipoprotein receptor-related protein 1target
TenecteplasePlasminogentarget
Interferon gamma-1bInterferon gamma receptor 1target
Interferon gamma-1bInterferon gamma receptor 2target
Interferon gamma-1bCytochrome P450 1A2enzyme
DesmopressinVasopressin V1a receptortarget
DesmopressinVasopressin V1b receptortarget
DesmopressinVasopressin V2 receptortarget
DesmopressinProstaglandin G/H synthase 1enzyme
DesmopressinProstaglandin G/H synthase 2enzyme
Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
Coagulation factor VIIa Recombinant HumanTissue factortarget
Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
OprelvekinInterleukin-11 receptor subunit alphatarget
PaliferminFibroblast growth factor receptor 2target
PaliferminNeuropilin-1target
PaliferminFibroblast growth factor receptor 1target
PaliferminFibroblast growth factor receptor 4target
PaliferminFibroblast growth factor receptor 3target
PaliferminBasement membrane-specific heparan sulfate proteoglycan core proteintarget
GlucagonGlucagon receptortarget
GlucagonGlucagon-like peptide 2 receptortarget
GlucagonGlucagon-like peptide 1 receptortarget
AldesleukinInterleukin-2 receptor subunit betatarget
AldesleukinInterleukin-2 receptor subunit alphatarget
AldesleukinCytokine receptor common subunit gammatarget
AldesleukinProstaglandin G/H synthase 2enzyme
AldesleukinCytosolic phospholipase A2enzyme
AldesleukinCytochrome P450 3A4enzyme
AldesleukinXanthine dehydrogenase/oxidaseenzyme
AldesleukinCytochrome P450 2E1enzyme
Botulinum Toxin Type BVesicle-associated membrane protein 1target
Botulinum Toxin Type BVesicle-associated membrane protein 2target
Botulinum Toxin Type BSynaptotagmin-2target
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
CetrorelixLutropin-choriogonadotropic hormone receptortarget
CetrorelixGonadotropin-releasing hormone receptortarget
AdalimumabTumor necrosis factortarget
AbciximabIntegrin beta-3target
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AbciximabIntegrin alpha-IIbtarget
AbciximabVitronectintarget
Drotrecogin alfaCoagulation factor VIIItarget
Drotrecogin alfaCoagulation factor Vtarget
Drotrecogin alfaPlasminogen activator inhibitor 1target
Drotrecogin alfaThrombomodulintarget
Drotrecogin alfaVitamin K-dependent protein Starget
Drotrecogin alfaProthrombintarget
Drotrecogin alfaPlatelet factor 4target
Drotrecogin alfaPlasma serine protease inhibitortarget
Drotrecogin alfaSerpin B6target
Drotrecogin alfaEndothelial protein C receptortarget
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
Indium In-111 satumomab pendetideTumor-associated glycoprotein 72 (TAG-72)target
Alpha-1-proteinase inhibitorNeutrophil elastasetarget
Interferon beta-1aInterferon alpha/beta receptor 1target
Interferon beta-1aInterferon alpha/beta receptor 2target
Interferon beta-1aCytochrome P450 1A2enzyme
Albumin humanNitric oxidetarget
InfliximabTumor necrosis factortarget
FollitropinFollicle-stimulating hormone receptortarget
VasopressinVasopressin V1a receptortarget
VasopressinVasopressin V2 receptortarget
VasopressinVasopressin V1b receptortarget
VasopressinCanalicular multispecific organic anion transporter 1transporter
Interferon beta-1bInterferon alpha/beta receptor 1target
Interferon beta-1bInterferon alpha/beta receptor 2target
Interferon beta-1bCytochrome P450 1A2enzyme
Interferon alfacon-1Interferon alpha/beta receptor 1target
Interferon alfacon-1Interferon alpha/beta receptor 2target
Interferon alfacon-1Cytochrome P450 1A2enzyme
Insulin porkInsulin receptortarget
Insulin porkHLA class II histocompatibility antigen, DQ alpha 2 chaintarget
Insulin porkHLA class II histocompatibility antigen, DQ beta 1 chaintarget
Insulin porkRetinoblastoma-associated proteintarget
Insulin porkCathepsin Dtarget
Insulin porkInsulin-like growth factor 1 receptortarget
Insulin porkInsulin-degrading enzymetarget
Insulin porkNeuroendocrine convertase 2target
Insulin porkCarboxypeptidase Etarget
Insulin porkNeuroendocrine convertase 1target
Insulin porkProtein NOV homologtarget
Insulin porkLow-density lipoprotein receptor-related protein 2target
Insulin porkInsulin-like growth factor-binding protein 7target
Insulin porkSynaptotagmin-like protein 4target
Insulin porkCytochrome P450 1A2enzyme
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
RituximabB-lymphocyte antigen CD20target
BasiliximabInterleukin-2 receptor subunit alphatarget
BasiliximabInterleukin-2 receptor subunit betatarget
MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
MuromonabT-cell surface glycoprotein CD3 delta chaintarget
MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
Ibritumomab tiuxetanB-lymphocyte antigen CD20target
TositumomabB-lymphocyte antigen CD20target
TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
Botulinum toxin type ASynaptosomal-associated protein 25target
Botulinum toxin type ARho-related GTP-binding protein RhoBtarget
StreptokinasePlasminogentarget
StreptokinaseProteinase-activated receptor 1target
StreptokinaseCytosolic phospholipase A2enzyme
AlemtuzumabCAMPATH-1 antigentarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Capromab pendetideGlutamate carboxypeptidase 2target
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
FelypressinVasopressin V1a receptortarget
EfalizumabIntegrin alpha-Ltarget
EfalizumabIntegrin alpha-Xtarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
FilgrastimGranulocyte colony-stimulating factor receptortarget
FilgrastimNeutrophil elastasetarget
BecaplerminPlatelet-derived growth factor receptor betatarget
BecaplerminAlpha-2-macroglobulintarget
BecaplerminPlatelet-derived growth factor receptor alphatarget
Agalsidase betaGlobotriaosylceramidetarget
NatalizumabIntegrin alpha-4target
NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
NatalizumabIntercellular adhesion molecule 1target
EnfuvirtideEnvelope glycoproteintarget
EnfuvirtideCytochrome P450 2C19enzyme
EnfuvirtideCytochrome P450 2E1enzyme
PalivizumabFusion glycoprotein F0target
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
PalivizumabComplement C1r subcomponenttarget
PalivizumabComplement C1q subcomponent subunit Atarget
PalivizumabComplement C1q subcomponent subunit Btarget
PalivizumabComplement C1q subcomponent subunit Ctarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabInterleukin-2 receptor subunit alphatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DaclizumabComplement C1r subcomponenttarget
DaclizumabComplement C1q subcomponent subunit Atarget
DaclizumabComplement C1q subcomponent subunit Btarget
DaclizumabComplement C1q subcomponent subunit Ctarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaclizumabInterleukin-2 receptor subunit betatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
Technetium Tc-99m arcitumomabCarcinoembryonic antigen-related cell adhesion molecule 1target
CitrullineNitric oxide synthase, endothelialtarget
CitrullineArgininosuccinate synthasetarget
CitrullineN(G),N(G)-dimethylarginine dimethylaminohydrolase 2target
CitrullineArgininosuccinate synthetase, isoform CRA_atarget
CitrullineN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
CitrullineOrnithine carbamoyltransferase, mitochondrialtarget
CitrullineNitric oxide synthase, braintarget
CitrullineNitric oxide synthase, inducibletarget
CitrullineProtein-arginine deiminase type-4target
CitrullineProtein-arginine deiminase type-6target
CitrullineProtein-arginine deiminase type-1target
CitrullineProtein-arginine deiminase type-3target
CitrullineProtein-arginine deiminase type-2target
CitrullineSolute carrier family 22 member 6transporter
PentagastrinGastrin/cholecystokinin type B receptortarget
PentagastrinCholinesteraseenzyme
GonadorelinGonadotropin-releasing hormone receptortarget
GonadorelinPutative gonadotropin-releasing hormone II receptortarget
NafarelinGonadotropin-releasing hormone receptortarget
NafarelinPutative gonadotropin-releasing hormone II receptortarget
ColistinBacterial outer membranetarget
Aminolevulinic acidDelta-aminolevulinic acid dehydratasetarget
Aminolevulinic acidSolute carrier family 15 member 1transporter
Aminolevulinic acidSolute carrier family 15 member 2transporter
ColistimethateBacterial outer membranetarget
EculizumabComplement C5target
PanitumumabEpidermal growth factor receptortarget
RanibizumabVascular endothelial growth factor Atarget
MecaserminInsulin-like growth factor 1 receptortarget
MecaserminInsulin-like growth factor-binding protein 3target
MecaserminInsulin receptortarget
MecaserminCation-independent mannose-6-phosphate receptortarget
MecaserminInsulin-like growth factor-binding protein 3carrier
MecaserminInsulin-like growth factor-binding protein complex acid labile subunitcarrier
MecaserminInsulin-like growth factor-binding protein 1carrier
MecaserminInsulin-like growth factor-binding protein 2carrier
MecaserminInsulin-like growth factor-binding protein 4carrier
MecaserminInsulin-like growth factor-binding protein 5carrier
MecaserminInsulin-like growth factor-binding protein 6carrier
PramlintideReceptor activity-modifying protein 1target
PramlintideReceptor activity-modifying protein 2target
PramlintideReceptor activity-modifying protein 3target
PramlintideCalcitonin receptortarget
GalsulfasePerilipin-3target
GalsulfaseDermatan sulfatetarget
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
TetracosactideAdrenocorticotropic hormone receptortarget
CorticotropinAdrenocorticotropic hormone receptortarget
CorticotropinCorticoliberintarget
Corticotropin3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
Corticotropin25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
Corticotropin1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
CorticotropinCytochrome P450 3A4enzyme
Insulin glulisineInsulin receptortarget
Insulin glulisineInsulin-like growth factor 1 receptortarget
Insulin glulisineCytochrome P450 1A2enzyme
CalciumProtein S100-Btarget
CalciumCalpastatintarget
CalciumCartilage oligomeric matrix proteintarget
CalciumCalmodulintarget
CalciumSpectrin beta chain, non-erythrocytic 1target
CalciumVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
CalciumTroponin C, skeletal muscletarget
CalciumTroponin C, slow skeletal and cardiac musclestarget
CalciumCalcium-transporting ATPase type 2C member 1target
CalciumAmiloride-sensitive amine oxidase [copper-containing]target
CalciumProtein S100-A13target
CalciumAlkaline phosphatase, placental typetarget
CalciumProtein S100-A8target
CalciumProtein S100-A9target
CalciumProtein S100-A2target
CalciumCeruloplasmintarget
CalciumBone morphogenetic protein 4target
CalciumMatrix Gla proteintarget
CalciumProtocadherin-19target
CalciumProgrammed cell death protein 6target
Bacteriochlorophyll ABacteriochlorophyll a proteintarget
Bacteriochlorophyll ABacteriochlorophyll a proteintarget
Molybdenum cofactorAldehyde oxidoreductasetarget
Platelet Activating FactorGanglioside GM2 activatortarget
Platelet Activating FactorP-glycoprotein 1transporter
Platelet Activating FactorPlatelet-activating factor receptortarget
TerlipressinVasopressin V1a receptortarget
TerlipressinVasopressin V2 receptortarget
TerlipressinVasopressin V1b receptortarget
VapreotideNeurokinin 1 receptortarget
VapreotideSomatostatin receptor type 2target
VapreotideSomatostatin receptor type 5target
VapreotideCytochrome P450 3A4enzyme
NesiritideAtrial natriuretic peptide receptor 1target
NesiritideAtrial natriuretic peptide receptor 2target
NesiritideAtrial natriuretic peptide receptor 3target
GaliximabT-lymphocyte activation antigen CD80target
DesmoteplasePlasminogentarget
AfamelanotideMelanocyte-stimulating hormone receptortarget
AfelimomabTumor necrosis factortarget
EpratuzumabB-cell receptor CD22target
OregovomabMucin-16target
Tigapotide40S ribosomal protein SAtarget
IGN311Epidermal growth factor receptortarget
IGN311Receptor tyrosine-protein kinase erbB-2target
LancovutideCytosolic phospholipase A2enzyme
REV131Histamine H4 receptortarget
AbaloparatideParathyroid hormone/parathyroid hormone-related peptide receptortarget
LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
LeptinLeptin receptortarget
MatuzumabEpidermal growth factor receptortarget
FontolizumabInterferon gammatarget
NN344Insulin receptortarget
NN344Cytochrome P450 1A2enzyme
CR002Platelet-derived growth factor Dtarget
CR665Kappa-type opioid receptortarget
ElafinNeutrophil elastasetarget
ElafinMyeloblastintarget
ElafinMyeloperoxidaseenzyme
RozrolimupabRhesus blood group D antigentarget
Interferon alfaInterferon alpha/beta receptor 1target
Interferon alfaCytochrome P450 1A2enzyme
GlatiramerHLA class II histocompatibility antigen, DRB1-1 beta chaintarget
Hepatitis B Immune GlobulinHBsAgtarget
keyhole limpet hemocyaninInterleukin-2target
Cintredekin BesudotoxInterleukin-13target
Oportuzumab monatoxEpithelial cell adhesion moleculetarget
RomiplostimThrombopoietin receptortarget
CorticorelinDopamine beta-hydroxylaseenzyme
Albinterferon Alfa-2BCytochrome P450 1A2enzyme
TifuvirtidePlasma serine protease inhibitortarget
LJP 1082Beta-2-glycoprotein 1target
BriakinumabInterleukin-12 subunit betatarget
BriakinumabInterleukin-23 subunit alphatarget
RamucirumabVascular endothelial growth factor receptor 2target
FarletuzumabFolate receptor alphatarget
UstekinumabInterleukin-12 subunit betatarget
UstekinumabInterleukin-23target
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
Thrombomodulin AlfaCoagulation factor Vtarget
Thrombomodulin AlfaProthrombintarget
PRO-542Free fatty acid receptor 4target
TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
RI 624Beta-nerve growth factortarget
MYO-029Growth/differentiation factor 8target
PegdinetanibVascular endothelial growth factor receptor 2target
CTCE-0214Stromal cell-derived factor 1target
LeronlimabC-C chemokine receptor type 5target
Glembatumumab vedotinTransmembrane glycoprotein NMBtarget
OlaratumabPlatelet-derived growth factor receptor alphatarget
TB-402Coagulation factor VIIItarget
Caplacizumabvon Willebrand factortarget
IMC-1C11Vascular endothelial growth factor receptor 1target
IMC-1C11Vascular endothelial growth factor receptor 2target
IMC-1C11Vascular endothelial growth factor receptor 3target
EldelumabC-X-C motif chemokine 10target
IRL-1620Endothelin B receptortarget
LumiliximabLow affinity immunoglobulin epsilon Fc receptortarget
CanakinumabInterleukin-1 betatarget
IpilimumabCytotoxic T-lymphocyte protein 4target
IcatibantB2 bradykinin receptortarget
IcatibantAminopeptidase Ntarget
ClenoliximabT-cell surface glycoprotein CD4target
LanoteplaseUrokinase plasminogen activator surface receptortarget
LanoteplaseFibrinogen alpha chaintarget
LanoteplaseKallikrein-1target
LanoteplaseLaminin subunit alpha-5target
LanoteplaseCoagulation factor Xtarget
LanoteplaseFibronectintarget
LanoteplasePlasminogen activator inhibitor 2target
LanoteplaseTetranectintarget
LanoteplaseKeratin, type II cytoskeletal 8target
LanoteplaseAnnexin A2target
LanoteplaseLaminin subunit beta-1target
LanoteplaseLaminin subunit gamma-1target
LanoteplaseLaminin subunit alpha-1target
LanoteplaseCalreticulintarget
LanoteplaseCalnexintarget
LanoteplaseProlow-density lipoprotein receptor-related protein 1target
LanoteplaseLaminin subunit alpha-3target
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
ElotuzumabSLAM family member 7target
AVE9633Myeloid cell surface antigen CD33target
AVE9633Cytochrome P450 3A4enzyme
CarotuximabEndoglintarget
XmAb 2513Tumor necrosis factor receptor superfamily member 8target
Coltuximab ravtansineB-lymphocyte antigen CD19target
Coltuximab ravtansineCytochrome P450 3A4enzyme
TeprotumumabInsulin-like growth factor 1 receptortarget
LucatumumabTumor necrosis factor receptor superfamily member 5target
PertuzumabReceptor tyrosine-protein kinase erbB-2target
SiplizumabT-cell surface antigen CD2target
RilonaceptInterleukin-1 betatarget
RilonaceptInterleukin-1 alphatarget
RilonaceptInterleukin-1 receptor antagonist proteintarget
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
Endostatin72 kDa type IV collagenasetarget
EndostatinMatrix metalloproteinase-9target
EndostatinCollagenase 3target
EndostatinFocal adhesion kinase 1target
EndostatinE-selectintarget
EndostatinCytochrome P450 19A1enzyme
SibrotuzumabSeprasetarget
OnerceptTumor necrosis factortarget
AMGN-0007Tumor necrosis factor ligand superfamily member 11target
ThrombopoietinThrombopoietin receptortarget
LabradimilB2 bradykinin receptortarget
BivatuzumabCD44 antigentarget
TG4010Mucin-1target
TG4010Interleukin-2target
LexatumumabTumor necrosis factor receptor superfamily member 10Btarget
ReslizumabInterleukin-5target
CatumaxomabEpithelial cell adhesion moleculetarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
MepolizumabInterleukin-5target
DenosumabTumor necrosis factor ligand superfamily member 11target
OfatumumabB-lymphocyte antigen CD20target
LiraglutideGlucagon-like peptide 1 receptortarget
LiraglutideDipeptidyl peptidase 4enzyme
LiraglutideNeprilysinenzyme
LiraglutideSerum albumincarrier
PasireotideSomatostatin receptor type 1target
PasireotideSomatostatin receptor type 2target
PasireotideSomatostatin receptor type 3target
PasireotideSomatostatin receptor type 5target
PasireotideCytochrome P450 3A4enzyme
GolimumabTumor necrosis factortarget
BelataceptT-lymphocyte activation antigen CD86target
BelataceptT-lymphocyte activation antigen CD80target
AprotininTrypsin-1target
AprotininChymotrypsinogen Btarget
AprotininPlasminogentarget
AprotininKallikrein-1target
AprotininCholinesteraseenzyme
BuserelinLutropin-choriogonadotropic hormone receptortarget
BuserelinGonadotropin-releasing hormone receptortarget
BuserelinCytochrome P450 19A1enzyme
GanirelixGonadotropin-releasing hormone receptortarget
HistrelinGonadotropin-releasing hormone receptortarget
LanreotideSomatostatin receptor type 2target
LanreotideSomatostatin receptor type 5target
LanreotideCytochrome P450 3A4enzyme
TriptorelinGonadotropin-releasing hormone receptortarget
DADLESolute carrier organic anion transporter family member 1B1transporter
DPDPESolute carrier organic anion transporter family member 1B3transporter
TesamorelinGrowth hormone-releasing hormone receptortarget
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
BelimumabTumor necrosis factor ligand superfamily member 13Btarget
AfliberceptVascular endothelial growth factor Atarget
AfliberceptPlacenta growth factortarget
AfliberceptVascular endothelial growth factor Btarget
TeduglutideGlucagon-like peptide 2 receptortarget
RaxibacumabProtective antigentarget
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
ObinutuzumabB-lymphocyte antigen CD20target
SecukinumabInterleukin-17Atarget
VedolizumabIntegrin alpha-4target
VedolizumabIntegrin beta-7target
NivolumabProgrammed cell death protein 1target
SiltuximabInterleukin-6target
SiltuximabCytochrome P450 3A4enzyme
PembrolizumabProgrammed cell death protein 1target
AlbiglutideGlucagon-like peptide 1 receptortarget
DulaglutideGlucagon-like peptide 1 receptortarget
MetreleptinLeptin receptortarget
BlinatumomabB-lymphocyte antigen CD19target
BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
Corticorelin ovine triflutateCorticotropin-releasing factor receptor 1target
DinutuximabGanglioside GD2target
SomatostatinSomatostatin receptor type 1target
SomatostatinSomatostatin receptor type 2target
SomatostatinSomatostatin receptor type 3target
SomatostatinSomatostatin receptor type 4target
SomatostatinSomatostatin receptor type 5target
SomatostatinP-glycoprotein 1transporter
SomatostatinCytochrome P450 3A4enzyme
AncestimMast/stem cell growth factor receptor Kittarget
Asfotase alfaSphingosine 1-phosphate receptor 1target
Asfotase alfaPyrophosphatetarget
Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
Turoctocog alfaCoagulation factor IXtarget
Turoctocog alfaCoagulation factor Xtarget
Turoctocog alfaProthrombintarget
Peginterferon beta-1aCytochrome P450 1A2enzyme
Chorionic Gonadotropin (Human)Lutropin-choriogonadotropic hormone receptortarget
Protamine sulfateCoagulation factor Xtarget
Protamine sulfateAntithrombin-IIItarget
PolaprezincTumor necrosis factortarget
PolaprezincInterleukin-6target
PolaprezincInterleukin-3target
PolaprezincSuperoxide dismutase [Cu-Zn]enzyme
PolaprezincHeme oxygenase 1enzyme
PolaprezincSuperoxide dismutase [Mn], mitochondrialenzyme
PolaprezincGlutathione S-transferase theta-1enzyme
PolaprezincGlutathione peroxidase 1enzyme
PolaprezincPeroxiredoxin-1enzyme
PolaprezincPeroxiredoxin-5, mitochondrialenzyme
PolaprezincVascular endothelial growth factor receptor 1target
PolaprezincBeta-nerve growth factortarget
PolaprezincPlatelet-derived growth factor receptor betatarget
PolaprezincHeat shock protein HSP 90-alphatarget
PolaprezincHeat shock protein HSP 90-betatarget
AlirocumabProprotein convertase subtilisin/kexin type 9target
EvolocumabProprotein convertase subtilisin/kexin type 9enzyme
DaratumumabADP-ribosyl cyclase 1target
ProtirelinThyrotropin Releasing Hormone Receptortarget
NecitumumabEpidermal growth factor receptortarget
DesirudinCarboxypeptidase A1enzyme
ThrombinProteinase-activated receptor 1target
ThrombinProteinase-activated receptor 4target
ThrombinCoagulation factor XItarget
ThrombinCoagulation factor XIII A chaintarget
ThrombinCoagulation factor XIII B chaintarget
ThrombinFibrinogen alpha chaintarget
ThrombinFibrinogen beta chaintarget
ThrombinFibrinogen gamma chaintarget
ThrombinCoagulation factor Vtarget
ThrombinCoagulation factor VIIItarget
ProthrombinFibrinogen alpha chaintarget
ProthrombinFibrinogen beta chaintarget
ProthrombinCoagulation factor XIII A chaintarget
ProthrombinCarboxypeptidase B2target
ProthrombinCoagulation factor Xenzyme
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
IxekizumabInterleukin-17Atarget
AtezolizumabProgrammed cell death 1 ligand 1target
Antithrombin III humanAntithrombin-IIItarget
Dibotermin alfaBone morphogenetic protein receptor type-1Atarget
Dibotermin alfaBone morphogenetic protein receptor type-2target
BremelanotideMelanocyte-stimulating hormone receptortarget
BremelanotideMelanocortin receptor 4target
BremelanotideMelanocortin receptor 3target
BremelanotideMelanocortin receptor 5target
BremelanotideAdrenocorticotropic hormone receptortarget
DurvalumabProgrammed cell death 1 ligand 1target
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
GuselkumabInterleukin-23 subunit alphatarget
Angiotensin IIType-1 angiotensin II receptortarget
RomosozumabSclerostintarget
AvelumabProgrammed cell death 1 ligand 1target
OcrelizumabB-lymphocyte antigen CD20target
Lorvotuzumab mertansineCytochrome P450 3A4enzyme
SotaterceptActivin receptor type-2Atarget
GevokizumabInterleukin-1 betatarget
DupilumabInterleukin-4 receptor subunit alphatarget
Polatuzumab vedotinCytochrome P450 3A4enzyme
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintransporter
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
CixutumumabInsulin-like growth factor 1 receptortarget
Mirvetuximab SoravtansineCytochrome P450 3A4enzyme
MogamulizumabC-C chemokine receptor type 4target
InebilizumabB-lymphocyte antigen CD19target
DacetuzumabTumor necrosis factor receptor superfamily member 5target
IbalizumabT-cell surface glycoprotein CD4target
IbalizumabC-C chemokine receptor type 5target
IbalizumabC-X-C chemokine receptor type 4target
AmatuximabMesothelintarget
Sacituzumab govitecanTumor-associated calcium signal transducer 2target
Sacituzumab govitecanDNA topoisomerase 1target
Sacituzumab govitecanFar upstream element-binding protein 1target
Sacituzumab govitecanUDP-glucuronosyltransferase 1-1enzyme
Von Willebrand Factor HumanCoagulation factor VIIItarget
Von Willebrand Factor HumanCollagen alpha-1(I) chaintarget
Von Willebrand Factor HumanA disintegrin and metalloproteinase with thrombospondin motifs 13enzyme
LenograstimGranulocyte colony-stimulating factor receptortarget
Protein S humanCoagulation factor Vtarget
Protein S humanCoagulation factor Xtarget
Protein S humanVitamin K-dependent protein Ctarget
Coagulation factor VII humanTissue factortarget
Coagulation factor VII humanCoagulation factor Xtarget
Coagulation factor VII humanCoagulation factor IXtarget
Antihemophilic factor humanCoagulation factor IXtarget
Antihemophilic factor humanCoagulation factor Xtarget
Antihemophilic factor humanVitamin K-dependent protein Cenzyme
LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
EmicizumabCoagulation factor IXtarget
EmicizumabCoagulation factor Xtarget
SemaglutideSerum albumincarrier
SemaglutideDipeptidyl peptidase 4enzyme
SemaglutideNeprilysinenzyme
SemaglutideGlucagon-like peptide 1 receptortarget
SemaglutideLipoprotein lipaseenzyme
SemaglutideAlpha-amylase 1enzyme
Nonacog beta pegolCoagulation factor VIItarget
Nonacog beta pegolCoagulation factor VIIItarget
Nonacog beta pegolCoagulation factor Xtarget
BesilesomabCarcinoembryonic antigentarget
Moroctocog alfaCoagulation factor Xtarget
Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
Moroctocog alfaCoagulation factor IXtarget
Moroctocog alfaAsialoglycoprotein receptor 2target
Moroctocog alfa78 kDa glucose-regulated proteintarget
Moroctocog alfaCalreticulintarget
Moroctocog alfaCalnexintarget
Moroctocog alfaProtein ERGIC-53target
Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
Moroctocog alfaMultiple coagulation factor deficiency protein 2target
Moroctocog alfavon Willebrand factortarget
Moroctocog alfaProthrombinenzyme
Moroctocog alfaVitamin K-dependent protein Cenzyme
TildrakizumabInterleukin-23target
TildrakizumabCytochrome P450 4A11enzyme
ErenumabCalcitonin gene-related peptide type 1 receptortarget
FremanezumabCalcitonin gene-related peptide 1target
FremanezumabCalcitonin gene-related peptide 2target
Secretin humanSecretin receptortarget
Andexanet alfaTissue factor pathway inhibitortarget
LanadelumabPlasma kallikreintarget
Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factortarget
Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factorcarrier
LypressinVasopressin V1a receptortarget
LypressinVasopressin V2 receptortarget
LypressinVasopressin V1b receptortarget
LypressinCanalicular multispecific organic anion transporter 1transporter
Moxetumomab PasudotoxB-cell receptor CD22target
Moxetumomab PasudotoxElongation factor 2target
ElapegademaseAdenosinetarget
LebrikizumabInterleukin-13target
LebrikizumabIL13 proteintarget
BenralizumabInterleukin-5 receptor subunit alphatarget
BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
ZalutumumabEpidermal growth factor receptortarget
PlozalizumabC-C chemokine receptor type 2target
SifalimumabInterferon alpha-2target
EmapalumabInterferon gammatarget
Turoctocog alfa pegolVitamin K-dependent protein Cenzyme
Turoctocog alfa pegolCoagulation factor Xenzyme
Turoctocog alfa pegolCoagulation factor IXtarget
Turoctocog alfa pegolCoagulation factor Xtarget
Turoctocog alfa pegolProthrombintarget
Turoctocog alfa pegolvon Willebrand factorcarrier
Polymyxin BBacterial outer membranetarget
Polymyxin BSolute carrier family 15 member 2transporter
GirentuximabCarbonic anhydrase 9target
GirentuximabInterleukin-2target
RisankizumabInterleukin-23target
RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
RegramostimGM-CSF receptor alpha subunittarget
RegramostimCholinesteraseenzyme
Sar9, Met (O2)11-Substance PCytochrome P450 19A1enzyme
Sar9, Met (O2)11-Substance PCholinesteraseenzyme
Sar9, Met (O2)11-Substance PProstaglandin G/H synthase 2enzyme
IsatuximabADP-ribosyl cyclase 1target
Human interferon betaCytochrome P450 1A2enzyme
Human interferon betaInterferon alpha/beta receptor 1target
Human interferon betaSerum albumincarrier
Interferon alfa-2cCytochrome P450 1A2enzyme
CT-011Programmed cell death protein 1target
Contulakin-GVoltage-dependent N-type calcium channel subunit alpha-1Btarget
GlucarpidaseMethotrexatetarget
Thrombin alfaCoagulation factor VIIItarget
Thrombin alfaCoagulation factor Vtarget
Thrombin alfaFibrinogen alpha chaintarget
Thrombin alfaFibrinogen beta chaintarget
Thrombin alfaFibrinogen gamma chaintarget
RavulizumabComplement C5target
Depatuxizumab mafodotinEpidermal growth factor receptortarget
Depatuxizumab mafodotinTubulin beta chaintarget
UrelumabTumor necrosis factor receptor superfamily member 9target
BezlotoxumabClostridium difficile Toxin Btarget
Anti-inhibitor coagulant complexCoagulation factor Xtarget
Anti-inhibitor coagulant complexProthrombintarget
Anti-inhibitor coagulant complexFibrinogen alpha chaintarget
Anti-inhibitor coagulant complexFibrinogen beta chaintarget
Anti-inhibitor coagulant complexCoagulation factor XIII A chaintarget
Anti-inhibitor coagulant complexCoagulation factor Vtarget
Anti-inhibitor coagulant complexCoagulation factor VIIItarget
Anti-inhibitor coagulant complexCoagulation factor VIItarget
Anti-inhibitor coagulant complexProthrombinenzyme
Anti-inhibitor coagulant complexCoagulation factor VIIenzyme
Anti-inhibitor coagulant complexCoagulation factor VIIIenzyme
Anti-inhibitor coagulant complexCoagulation factor IXenzyme
Anti-inhibitor coagulant complexCoagulation factor Venzyme
Cerliponase alfaCation-independent mannose-6-phosphate receptortarget
TisagenlecleucelB-lymphocyte antigen CD19target
Albutrepenonacog alfaCoagulation factor Xtarget
Albutrepenonacog alfaCoagulation factor VIIIenzyme
BurosumabFibroblast growth factor 23target
EptinezumabCalcitonin gene-related peptide 1target
EptinezumabCalcitonin gene-related peptide 2target
GalcanezumabCalcitonin gene-related peptide 1target
GalcanezumabCalcitonin gene-related peptide 2target
CemiplimabProgrammed cell death protein 1target
TagraxofuspInterleukin-3 receptor subunit alphatarget
TagraxofuspADP-ribosylation factor-like protein 2target
BrolucizumabVascular endothelial growth factor Atarget
Trastuzumab deruxtecanP-glycoprotein 1transporter
Trastuzumab deruxtecanHigh affinity immunoglobulin gamma Fc receptor Itarget
Trastuzumab deruxtecanDNA topoisomerase 1target
Trastuzumab deruxtecanLysosomal alpha-glucosidaseenzyme
Trastuzumab deruxtecanDNA topoisomerase 1enzyme
Trastuzumab deruxtecanCathepsin Benzyme
Trastuzumab deruxtecanCathepsin L1enzyme
Trastuzumab deruxtecanCytochrome P450 3A4enzyme
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B1transporter
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B3transporter
Trastuzumab deruxtecanMultidrug and toxin extrusion protein 2transporter
Trastuzumab deruxtecanMultidrug resistance-associated protein 1transporter
Trastuzumab deruxtecanATP-binding cassette sub-family G member 2transporter